References
- Ghobrial I M, Habermann T M, Macon W R, Ristow K M, Larson T S, Walker R C, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?. Transplantation 2005; 79: 244–247
- Armitage J M, Kormos R L, Stuart R S, Fricker F J, Griffith B P, Nalesnik M, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart and Lung Transplantation 1991; 10: 877–887
- Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organization classification of tumors. Tumours of Haematopoietic and Lymphoid Tissues 2001; 264–269
- Swerdlow S H. Classification of the post transplant lymphoproliferative disorders: from the past to the present. Seminar in Diagnostic Pathology 1997; 14: 2
- Nalesnik M A. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. Recent Results in Cancer Res 2002; 159: 9–18
- Shahinian V B, Muirhead N, Jevnikar A M, Leckie S H, Khakhar A K, Luke P P, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851–856
- Dotti G, Fiocchi R, Motta T, Gamba A, Gotti E, Gridelli B, et al. Epstein-Barr virus-negative lymphoproliferative disorders in long-term survivors after heart, kidney and liver transplant. Transplantation 2000; 69: 827–833
- Connel W R, Kamm M A, Dickson M, Balkwill A M, Ritchie J K, Lennard-Jones J E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249
- Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nature Reviews in Immunology 2003; 10: 801–812
- Pirsch J D, Stratta R J, Sollinger H W, Hafez G R, D'Alessandro A M, Kalayoglu M, Belzer F O. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86: 241
- Mamzer-Bruneel M F, Lome C, Morelon E, Levy V, Bourquelot P, Jacobs F, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622
- Verschuuren E A, Stevens S J, Van Imhoff G W, Middeldorp J M, de Boer C, Koeter G, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002; 73: 100